James Royal
Internal Medicine · Opelika, ALNPI 1790872174
Payments from drug & device makers
Across 534 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Pfizer$1K
- Novo Nordisk$1K
- GSK$925
- Lilly USA, LLC$682
- Boehringer Ingelheim$498
- plus $3K from 29 others
What the payments were for
- Food & beverage$8,09599%
- Education$741%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 85 | $1,359 |
| Pfizer | 64 | $1,007 |
| Novo Nordisk | 65 | $1,003 |
| GSK | 67 | $925 |
| Lilly USA, LLC | 52 | $682 |
| Boehringer Ingelheim | 36 | $498 |
| Abbott | 17 | $333 |
| AbbVie(2 entities) | 20 | $295 |
| Astellas Pharma US Inc | 16 | $283 |
| Merck | 18 | $239 |
| Amgen | 14 | $215 |
| Novartis | 10 | $145 |
| Johnson & Johnson(2 entities) | 9 | $137 |
| Xeris Pharmaceuticals, Inc. | 6 | $130 |
| Bayer | 7 | $126 |
| Kowa Pharmaceuticals America, Inc. | 7 | $101 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $93 |
| Esperion Therapeutics, Inc. | 4 | $68 |
| Sanofi-aventis U.S. LLC | 4 | $64 |
| Amarin Pharma, Inc. | 3 | $63 |
| Exact Sciences | 4 | $55 |
| Dexcom, Inc. | 2 | $46 |
| Phathom Pharmaceuticals, Inc. | 3 | $45 |
| Philips North America LLC | 2 | $30 |
| Eyevance Pharmaceuticals LLC | 2 | $29 |
| Hikma Pharmaceuticals USA | 2 | $29 |
| Paratek Pharmaceuticals, Inc. | 2 | $28 |
| Pharmacosmos Therapeutics Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$8,169 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 310 | $311,482 |
| JardianceEmpagliflozin | 149 | $158,011 |
| EliquisApixaban | 214 | $135,147 |
| MounjaroTirzepatide | 96 | $125,755 |
| TrulicityDulaglutide | 112 | $109,576 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $64,825 |
| JanuviaSitagliptin Phosphate | 51 | $60,221 |
| JanumetSitagliptin Phos/Metformin Hcl | 49 | $43,205 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 123 | $39,313 |
| FarxigaDapagliflozin Propanediol | 47 | $31,396 |
| RybelsusSemaglutide | 25 | $31,339 |
| XareltoRivaroxaban | 76 | $30,034 |
| Tresiba Flextouch U-100Insulin Degludec | 59 | $24,487 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $23,844 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $21,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp | $1,003 | $351,633347 claims |
| Lilly USA, LLCMounjaro, Trulicity | $682 | $235,331208 claims |
| PfizerEliquis, Abrysvo | $1,007 | $174,459337 claims |
| Boehringer IngelheimJardiance | $498 | $158,011149 claims |
| MerckJanuvia, Janumet, Belsomra | $239 | $117,293132 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta | $925 | $83,927124 claims |
| Johnson & JohnsonXarelto, Invokana | $137 | $37,61689 claims |
| AstraZenecaFarxiga | $1,359 | $31,39647 claims |
| AbbVieLinzess | $295 | $19,18527 claims |
| Astellas Pharma US IncMyrbetriq | $283 | $11,07823 claims |
| NovartisEntresto | $145 | $9,21212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Opelika
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
- Gregory FlippoTrussville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.